相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Why Do So Many Nonalcoholic Steatohepatitis Trials Fail?
Vlad Ratziu et al.
GASTROENTEROLOGY (2023)
Human hepatic in vitro models reveal distinct anti-NASH potencies of PPAR agonists
Joost Boeckmans et al.
CELL BIOLOGY AND TOXICOLOGY (2021)
Elafibranor: a potential drug for the treatment of nonalcoholic steatohepatitis (NASH)
Menso J. Westerouen Van Meeteren et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2020)
Targeting FGF21 for the Treatment of Nonalcoholic Steatohepatitis
Mohammad Zarei et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2020)
Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges
Jean-Francois Dufour et al.
GUT (2020)
Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages
Sander Lefere et al.
JOURNAL OF HEPATOLOGY (2020)
Autophagy in liver diseases: Time for translation?
Manon Allaire et al.
JOURNAL OF HEPATOLOGY (2019)
PPARδ attenuates hepatic steatosis through autophagy-mediated fatty acid oxidation
Lei Tong et al.
CELL DEATH & DISEASE (2019)
A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis
Scott L. Friedman et al.
HEPATOLOGY (2018)
GW0742 (PPAR-beta agonist) attenuates hepatic endoplasmic reticulum stress by improving hepatic energy metabolism in high-fat diet fed mice
Flavia Maria Silva-Veiga et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2018)
Hepatic regulation of VLDL receptor by PPAR beta/delta and FGF21 modulates non-alcoholic fatty liver disease
Mohammad Zarei et al.
MOLECULAR METABOLISM (2018)
Ligand-Dependent Interaction of PPARδ With T-Cell Protein Tyrosine Phosphatase 45 Enhances Insulin Signaling
Taesik Yoo et al.
DIABETES (2018)
Fatty liver and FGF21 physiology
Eleftheria Maratos-Flier
EXPERIMENTAL CELL RESEARCH (2017)
Treatment options for nonalcoholic steatohepatitis - a safety evaluation
Danny Issa et al.
EXPERT OPINION ON DRUG SAFETY (2017)
Metabolomic Identification of Subtypes of Nonalcoholic Steatohepatitis
Cristina Alonso et al.
GASTROENTEROLOGY (2017)
NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice
Auvro R. Mridha et al.
JOURNAL OF HEPATOLOGY (2017)
Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance
Ruth C. R. Meex et al.
NATURE REVIEWS ENDOCRINOLOGY (2017)
The Selective Peroxisome Proliferator-Activated Receptor-Delta Agonist Seladelpar Reverses Nonalcoholic Steatohepatitis Pathology by Abrogating Lipotoxicity in Diabetic Obese Mice
Fahrettin Haczeyni et al.
HEPATOLOGY COMMUNICATIONS (2017)
Pathophysiology and Mechanisms of Nonalcoholic Fatty Liver Disease
Joel T. Haas et al.
ANNUAL REVIEW OF PHYSIOLOGY, VOL 78 (2016)
Heme-Regulated eIF2α Kinase Modulates Hepatic FGF21 and Is Activated by PPARβ/δ Deficiency
Mohammad Zarei et al.
DIABETES (2016)
Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
Vlad Ratziu et al.
GASTROENTEROLOGY (2016)
Global Epidemiology of Nonalcoholic Fatty Liver Disease-Meta-Analytic Assessment of Prevalence, Incidence, and Outcomes
Zobair M. Younossi et al.
HEPATOLOGY (2016)
Transcriptional control of physiological and pathological processes by the nuclear receptor PPARβ/δ
Nguan Soon Tan et al.
PROGRESS IN LIPID RESEARCH (2016)
Establishing the Role of PPARβ/δ in Carcinogenesis
Jeffrey M. Peters et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2015)
Peroxisome proliferator-activated receptor-delta agonist ameliorated inflammasome activation in nonalcoholic fatty liver disease
Hyun Jung Lee et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2015)
PPARα Is Required for PPAδ Action in Regulation of Body Weight and Hepatic Steatosis in Mice
Wojciech G. Garbacz et al.
PPAR RESEARCH (2015)
Circulating FGF21 Is Liver Derived and Enhances Glucose Uptake During Refeeding and Overfeeding
Kathleen R. Markan et al.
DIABETES (2014)
Roles for Chemokines in Liver Disease
Fabio Marra et al.
GASTROENTEROLOGY (2014)
Sterol Regulatory Element-binding Protein-1 (SREBP-1) Is Required to Regulate Glycogen Synthesis and Gluconeogenic Gene Expression in Mouse Liver
Rafaela Ruiz et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
PPARδ activation attenuates hepatic steatosis in Ldlr-/- mice by enhanced fat oxidation, reduced lipogenesis, and improved insulin sensitivity
Lazar A. Bojic et al.
JOURNAL OF LIPID RESEARCH (2014)
Upregulation of hepatic VLDLR via PPARα is required for the triglyceride-lowering effect of fenofibrate
Yang Gao et al.
JOURNAL OF LIPID RESEARCH (2014)
PHYSIOLOGICAL FUNCTIONS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR β
Jaap G. Neels et al.
PHYSIOLOGICAL REVIEWS (2014)
Clustering Nuclear Receptors in Liver Regeneration Identifies Candidate Modulators of Hepatocyte Proliferation and Hepatocarcinoma
Michele Vacca et al.
PLOS ONE (2014)
Dual Peroxisome Proliferator-Activated Receptor α/δ Agonist GFT505 Improves Hepatic and Peripheral Insulin Sensitivity in Abdominally Obese Subjects
Bertrand Cariou et al.
DIABETES CARE (2013)
Hepatoprotective Effects of the Dual Peroxisome Proliferator-Activated Receptor Alpha/Delta Agonist, GFT505, in Rodent Models of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
Bart Staels et al.
HEPATOLOGY (2013)
A diurnal serum lipid integrates hepatic lipogenesis and peripheral fatty acid use
Sihao Liu et al.
NATURE (2013)
PPARβ/δ modulates ethanol-induced hepatic effects by decreasing pyridoxal kinase activity
Maryam Goudarzi et al.
TOXICOLOGY (2013)
Lipoprotein metabolism in nonalcoholic fatty liver disease
Zhenghui Gordon Jiang et al.
JOURNAL OF BIOMEDICAL RESEARCH (2013)
Activating transcription factor 4-dependent induction of FGF21 during amino acid deprivation
Ana Luisa De Sousa-Coelho et al.
BIOCHEMICAL JOURNAL (2012)
The peroxisome proliferator-activated receptor (PPAR) β/δ agonist GW501516 inhibits IL-6-induced signal transducer and activator of transcription 3 (STAT3) activation and insulin resistance in human liver cells
L. Serrano-Marco et al.
DIABETOLOGIA (2012)
Lack of Overt FGF21 Resistance in Two Mouse Models of Obesity and Insulin Resistance
Clarence Hale et al.
ENDOCRINOLOGY (2012)
Peroxisome proliferator-activated receptor δ agonist attenuates hepatic steatosis by anti-inflammatory mechanism
Mi Young Lee et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2012)
Endocrine fibroblast growth factors 15/19 and 21: from feast to famine
Matthew J. Potthoff et al.
GENES & DEVELOPMENT (2012)
Ligand-dependent nucleo-cytoplasmic shuttling of peroxisome proliferator-activated receptors, PPARα and PPARγ
Tomoe Umemoto et al.
GENES TO CELLS (2012)
Liver X Receptor β and Peroxisome Proliferator-Activated Receptor δ Regulate Cholesterol Transport in Murine Cholangiocytes
Xuefeng Xia et al.
HEPATOLOGY (2012)
The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
Naga Chalasani et al.
HEPATOLOGY (2012)
Protection from liver fibrosis by a peroxisome proliferator-activated receptor δ agonist
Keiko Iwaisako et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
GW501516-activated PPARβ/δ promotes liver fibrosis via p38-JNK MAPK-induced hepatic stellate cell proliferation
Radina Kostadinova et al.
CELL AND BIOSCIENCE (2012)
Peroxisome proliferator-activated receptors and cancer: challenges and opportunities
Jihan Youssef et al.
BRITISH JOURNAL OF PHARMACOLOGY (2011)
Effects of the New Dual PPARα/δ Agonist GFT505 on Lipid and Glucose Homeostasis in Abdominally Obese Patients With Combined Dyslipidemia or Impaired Glucose Metabolism
Bertrand Cariou et al.
DIABETES CARE (2011)
The PPARβ/δ Activator GW501516 Prevents the Down-Regulation of AMPK Caused by a High-Fat Diet in Liver and Amplifies the PGC-1α-Lipin 1-PPARα Pathway Leading to Increased Fatty Acid Oxidation
Emma Barroso et al.
ENDOCRINOLOGY (2011)
Role of Peroxisome Proliferator-activated Receptor δ/β in Hepatic Metabolic Regulation
Sihao Liu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
MBX-8025, A Novel Peroxisome Proliferator Receptor-δ Agonist: Lipid and Other Metabolic Effects in Dyslipidemic Overweight Patients Treated with and without Atorvastatin
Harold E. Bays et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Endoplasmic reticulum stress in liver disease
Harmeet Malhi et al.
JOURNAL OF HEPATOLOGY (2011)
Obesity Is a Fibroblast Growth Factor 21 (FGF21)-Resistant State
Ffolliott M. Fisher et al.
DIABETES (2010)
Increased Fibroblast Growth Factor 21 in Obesity and Nonalcoholic Fatty Liver Disease
Jody Dushay et al.
GASTROENTEROLOGY (2010)
Transcriptional profiling reveals divergent roles of PPARα and PPARβ/δ in regulation of gene expression in mouse liver
Linda M. Sanderson et al.
PHYSIOLOGICAL GENOMICS (2010)
Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity
M. Mraz et al.
CLINICAL ENDOCRINOLOGY (2009)
Fibroblast Growth Factor 21 Reverses Hepatic Steatosis, Increases Energy Expenditure, and Improves Insulin Sensitivity in Diet-Induced Obese Mice
Jing Xu et al.
DIABETES (2009)
Circulating Fibroblast Growth Factor-21 Is Elevated in Impaired Glucose Tolerance and Type 2 Diabetes and Correlates With Muscle and Hepatic Insulin Resistance
Alberto O. Chavez et al.
DIABETES CARE (2009)
Circulating Fibroblast Growth Factor 21 Is Induced by Peroxisome Proliferator-Activated Receptor Agonists But Not Ketosis in Man
Constantinos Christodoulides et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Peroxisome proliferator-activated receptor delta activation leads to increased transintestinal cholesterol efflux
Carlos L. J. Vrins et al.
JOURNAL OF LIPID RESEARCH (2009)
AMPK in Health and Disease
Gregory R. Steinberg et al.
PHYSIOLOGICAL REVIEWS (2009)
Quantitative expression patterns of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) protein in mice
Elizabeth E. Girroir et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2008)
Alternative M2 activation of Kupffer cells by PPARδ ameliorates obesity-induced insulin resistance
Justin I. Odegaard et al.
CELL METABOLISM (2008)
Partial resistance to peroxisome proliferator-activated receptor-α agonists in ZDF rats is associated with defective hepatic rnitochondrial metabolism
Santhosh Satapati et al.
DIABETES (2008)
Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans
Xinmei Zhang et al.
DIABETES (2008)
Fibroblast Growth Factor 21 Corrects Obesity in Mice
Tamer Coskun et al.
ENDOCRINOLOGY (2008)
PPAR-beta/delta agonists for Type 2 diabetes and dyslipidemia: an adopted orphan still looking for a home
Andrew N. Billin
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2008)
Peroxisome proliferator-activated receptor-δ induces insulin-induced gene-1 and suppresses hepatic lipogenesis in obese diabetic mice
Xiaomei Qin et al.
HEPATOLOGY (2008)
Adipose fibroblast growth factor 21 is up-regulated by peroxisome proliferator-activated receptor γ and altered metabolic states
Eric S. Muise et al.
MOLECULAR PHARMACOLOGY (2008)
Ligand activation of peroxisome proliferator-activated receptor β/δ (PPARβ/δ) attenuates carbon tetrachloride hepatotoxicity by downregulating proinflammatory gene expression
Weiwei Shan et al.
TOXICOLOGICAL SCIENCES (2008)
Activation of peroxisome proliferator-activated receptor (PPAR)δ promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatly acid oxidation in moderately obese men
Ulf Riserus et al.
DIABETES (2008)
PPARδ as a therapeutic target in metabolic disease
Shannon M. Reilly et al.
FEBS LETTERS (2008)
Circulating FGF-21 levels in normal subjects and in newly diagnose patients with type 2 diabetes Mellitus
W. -W. Chen et al.
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES (2008)
Hepatic fibroblast growth factor 21 is regulated by PPARα and is a key mediator of hepatic lipid metabolism in ketotic states
Michael K. Badman et al.
CELL METABOLISM (2007)
Endocrine regulation of the fasting response by PPARα-mediated induction of fibroblast growth factor 21
Takeshi Inagaki et al.
CELL METABOLISM (2007)
Hepatic histology in obese patients undergoing bariatric surgery
Mariana Machado et al.
JOURNAL OF HEPATOLOGY (2006)
Long-term follow-up of patients with NAFLD and elevated liver enzymes
Mattias Ekstedt et al.
HEPATOLOGY (2006)
Peroxisome proliferator-activated receptor gamma as a drug target in the pathogenesis of insulin resistance
Liang Guo et al.
PHARMACOLOGY & THERAPEUTICS (2006)
Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARδ agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet
T Nagasawa et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2006)
PPARδ regulates glucose metabolism and insulin sensitivity
CH Lee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
FGF-21 as a novel metabolic regulator
A Kharitonenkov et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Reduced cholesterol absorption upon PPARδ activation coincides with decreased intestinal expression of NPC1L1
JN van der Veen et al.
JOURNAL OF LIPID RESEARCH (2005)
Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-δ accelerates intestinal adenoma growth
RA Gupta et al.
NATURE MEDICINE (2004)
Activation of peroxisome proliferator-activated receptor δ induces fatty acid β-oxidation in skeletal muscle and attenuates metabolic syndrome
T Tanaka et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference
BA Neuschwander-Tetri et al.
HEPATOLOGY (2003)
Peroxisome proliferator-activated receptor-beta signaling contributes to enhanced proliferation of hepatic stellate cells
K Hellemans et al.
GASTROENTEROLOGY (2003)
Selective cooperation between fatty acid binding proteins and peroxisome proliferator-activated receptors in regulating transcription
NS Tan et al.
MOLECULAR AND CELLULAR BIOLOGY (2002)
Mutant mammalian cells as tools to delineate the sterol regulatory element-binding protein pathway for feedback regulation of lipid synthesis
JL Goldstein et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2002)
Insulin resistance in type 2 diabetes: role of fatty acids
P Arner
DIABETES-METABOLISM RESEARCH AND REVIEWS (2002)
Differential gene regulation in human versus rodent hepatocytes by peroxisome proliferator-activated receptor (PPAR) α -: PPARα fails to induce peroxisome proliferation-associated genes in human cells independently of the level of receptor expression
JW Lawrence et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport
WR Oliver et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
分享论文
